Cargando…

Components of metabolic syndrome in patients with multiple myeloma and smoldering multiple myeloma

BACKGROUND: The prevalences of diabetes mellitus and hypertension, both of which are components of metabolic syndrome, are known to be increased among patients with multiple myeloma (MM), but remain undetermined among patients with smoldering MM (SMM). METHODS: Changes in various components of metab...

Descripción completa

Detalles Bibliográficos
Autores principales:	Markus, Efrat, Trestman, Svetlana, Cohen, Yael, Angel, Yoel, Sofer, Yael, Mittelman, Moshe, Avivi, Irit, Stern, Naftali, Izkhakov, Elena
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7260792/ https://www.ncbi.nlm.nih.gov/pubmed/32473631 http://dx.doi.org/10.1186/s12885-020-06976-1

Ejemplares similares

P966: SMOLDERING MULTIPLE MYELOMA (MM) PROGRESSING TO ACTIVE MM DURING FOLLOW-UP: REDUCED BONE DISEASE AND IMPROVED PROGRESSION-FREE AND OVERALL SURVIVAL COMPARED TO DE-NOVO NEWLY DIAGNOSED MM
por: Fridberg, Gil, et al.
Publicado: (2023)

Daratumumab in combination with proteasome inhibitors, rapidly decreases polyclonal immunoglobulins and increases infection risk among relapsed multiple myeloma patients: a single center retrospective study
por: Vitkon, Roy, et al.
Publicado: (2021)

Smoldering Multiple Myeloma
por: Gao, Minjie, et al.
Publicado: (2015)

P942: MULTIPLE MYELOMA OLIGOSECRETORY RELAPSE- A CROSS SECTIONAL HISTORICAL COHORT STUDY
por: Vaxman, Iuliana, et al.
Publicado: (2023)

Vagal Nerve Activity Predicts Prognosis in Diffused Large B-Cell Lymphoma and Multiple Myeloma
por: Atar, Or, et al.
Publicado: (2023)

Real‐world experience with belantamab mafodotin therapy for relapsed/refractory multiple myeloma: A multicentre retrospective study
por: Shragai, Tamir, et al.
Publicado: (2022)

Genomic patterns of progression in smoldering multiple myeloma
por: Bolli, Niccolò, et al.
Publicado: (2018)

Smoldering Multiple Myeloma Arising in Ulcerative Colitis
por: Yang, Xue, et al.
Publicado: (2018)

How we manage smoldering multiple myeloma
por: Romano, Alessandra, et al.
Publicado: (2020)

Recent Advances in the Management of Smoldering Multiple Myeloma
por: Madhira, Bhaskara Reddy, et al.
Publicado: (2020)

How We Approach Smoldering Multiple Myeloma
por: Raje, Noopur, et al.
Publicado: (2020)

Systemic Mastocytosis Associated with “Smoldering” Multiple Myeloma
por: Zanelli, Magda, et al.
Publicado: (2021)

What Is New in the Treatment of Smoldering Multiple Myeloma?
por: Bolli, Niccolo’, et al.
Publicado: (2021)

Risk Stratification and Treatment in Smoldering Multiple Myeloma
por: Lussier, Tyler, et al.
Publicado: (2021)

How I approach smoldering multiple myeloma
por: Vaxman, Iuliana, et al.
Publicado: (2022)

Smoldering multiple myeloma current treatment algorithms
por: Rajkumar, S. Vincent, et al.
Publicado: (2022)

International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)
por: Mateos, María-Victoria, et al.
Publicado: (2020)

Treatment of Smoldering Multiple Myeloma: Ready for Prime Time?
por: Kim, E. Bridget, et al.
Publicado: (2020)

Kidney transplantation for active multiple myeloma or smoldering myeloma: a case–control study
por: Kormann, Raphaël, et al.
Publicado: (2019)

The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
por: Boyle, Eileen M., et al.
Publicado: (2021)

Prevalence, incidence and survival of smoldering multiple myeloma in the United States
por: Ravindran, A, et al.
Publicado: (2016)

Systemic Mastocytosis with Smoldering Multiple Myeloma: Report of a Case
por: Ghanem, Sassine, et al.
Publicado: (2016)

Imaging of Monoclonal Gammapathy of Undetermined Significance and Smoldering Multiple Myeloma
por: Jamet, Bastien, et al.
Publicado: (2020)

Smoldering multiple myeloma revealed by superior ophthalmic vein thrombosis
por: Bouattour, Nadia, et al.
Publicado: (2020)

Genomics of Smoldering Multiple Myeloma: Time for Clinical Translation of Findings?
por: Lionetti, Marta, et al.
Publicado: (2021)

The Role of Monoclonal Antibodies in Smoldering and Newly Diagnosed Transplant-Eligible Multiple Myeloma
por: Zamagni, Elena, et al.
Publicado: (2020)

Smoldering multiple myeloma: prevalence and current evidence guiding treatment decisions
por: Blum, Agnieszka, et al.
Publicado: (2018)

Eosinophilic Fasciitis and Smoldering Multiple Myeloma: An Exceptional Association in Young Adults
por: Jabbouri, Rajaa, et al.
Publicado: (2022)

Mode of Progression in Smoldering Multiple Myeloma: A study of 406 patients
por: Rajkumar, S, et al.
Publicado: (2023)

Is aggressive treatment of smoldering myeloma the path to curing myeloma?
por: Chakraborty, Rajshekhar, et al.
Publicado: (2023)

Angiogenic cytokines profile in smoldering multiple myeloma: No difference compared to MGUS but altered compared to symptomatic myeloma
por: Gkotzamanidou, Maria, et al.
Publicado: (2013)

Novel therapies delay the progression of smoldering multiple myeloma: Case report and discussion
por: Jhaveri, A., et al.
Publicado: (2010)

Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma
por: Ravi, P, et al.
Publicado: (2016)

Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria
por: Lakshman, Arjun, et al.
Publicado: (2018)

Evolving changes in M-protein and hemoglobin as predictors for progression of smoldering multiple myeloma
por: Atrash, Shebli, et al.
Publicado: (2018)

Crohn's disease and smoldering multiple myeloma: a case report and literature review
por: Park, So Young, et al.
Publicado: (2017)

Gastrointestinal amyloidosis in a patient with smoldering multiple myeloma: A case report
por: Liu, Ai-Ling, et al.
Publicado: (2022)

Upper Gastrointestinal Bleeding from Gastric Amyloidosis in a Patient with Smoldering Multiple Myeloma
por: Gjeorgjievski, Mihajlo, et al.
Publicado: (2015)

Necrobiotic xanthogranuloma associated with smoldering multiple myeloma: satisfactory response to cyclophosphamide, dexamethasone, and thalidomide
por: de Mello, Renan Bernardes, et al.
Publicado: (2019)

Donor-Derived Smoldering Multiple Myeloma following a Hematopoietic Cell Transplantation for AML
por: Fakhri, Bita, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_olk75tt0g9m871c184agfp3s9d